Fine Foods & Pharmaceuticals Ntm Logo

Fine Foods & Pharmaceuticals Ntm

A CSDMO specializing in solid oral forms for the pharma and nutraceutical sectors.

FF | XMIL

Overview

Corporate Details

ISIN(s):
IT0005215329 (+1 more)
LEI:
8156009111DEE8553765
Country:
Italy
Address:
VIA BERLINO, 39 (ZINGONIA), 24040 VERDELLINO

Description

Fine Foods & Pharmaceuticals Ntm is an integrated Contract Sales and Development Manufacturing Organization (CSDMO) specializing in the development and contract manufacturing of products for third parties. The company's core expertise is in solid oral forms for the pharmaceutical and nutraceutical sectors. Its services also extend to the production of medical devices, cosmetics, and biocides. The organization applies a principle of scientific rigor across all its operations, emphasizing technological innovation, manufacturing excellence, and quality. With a significant portion of its workforce dedicated to science, the company acts as a strategic manufacturing partner to support client growth.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-22 10:18
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 15 DICEMBRE–19 DICEMBRE 2025 /…
English 543.8 KB
2025-12-15 10:22
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 8 DICEMBRE–12 DICEMBRE 2025 / …
English 547.1 KB
2025-12-09 10:37
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 1 DICEMBRE–5 DICEMBRE 2025 / T…
Italian 478.4 KB
2025-12-01 17:17
Allegato 3F / Annex 3F
Italian 28.6 KB
2025-12-01 11:19
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 24 NOVEMBRE – 28 NOVEMBRE 2025…
Italian 470.8 KB
2025-11-24 10:10
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 17 NOVEMBRE – 21 NOVEMBRE 2025…
Italian 515.0 KB
2025-11-17 13:16
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 10 NOVEMBRE – 14 NOVEMBRE 2025…
Italian 466.2 KB
2025-11-11 15:15
Interim Financial Report as of 30 September 2025
Italian 448.5 KB
2025-11-10 10:42
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 3 NOVEMBRE – 7 NOVEMBRE 2025 /…
Italian 463.4 KB
2025-11-06 15:18
Resoconto intermedio di gestione al 30 settembre 2025
Italian 400.6 KB
2025-11-06 13:38
Fine Foods confirms growth trajectory: revenue +7%, Adjusted EBITDA was €30.5 m…
English 644.7 KB
2025-11-06 13:37
Fine Foods consolida il percorso di crescita: ricavi +7%, EBITDA Adj. a €30,5 m…
Italian 639.5 KB
2025-11-04 10:09
Allegato 3F / Annex 3F
Italian 28.7 KB
2025-11-03 11:31
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 27 OTTOBRE – 31 OTTOBRE 2025 …
Italian 471.5 KB
2025-10-27 11:19
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 20 OTTOBRE – 24 OTTOBRE 2025 /…
Italian 449.3 KB

Automate Your Workflow. Get a real-time feed of all Fine Foods & Pharmaceuticals Ntm filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fine Foods & Pharmaceuticals Ntm

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fine Foods & Pharmaceuticals Ntm via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.